Docetaxel: A review of its role in breast cancer treatment

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 4, 1997, Pages 429-432

  Antoine, Eric Charles ^a,b   Rixe, Olivier ^a   Auclerc, Gérard ^a   Weil, Marise ^a   Khayat, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Service d'Informatique Medicale   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

BREAST CANCER; DEPOLYMERIZATION; DOSE RESPONSE; MICROTUBULE ASSEMBLY; MUCOSA INFLAMMATION; NEUTROPENIA; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; PACLITAXEL; REMISSION INDUCTION; SAFETY; TAXOIDS;

EID: 0030746389     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199708000-00023     Document Type: Review

References (38)

1. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. In: DeVita VT Jr, Hellman S, Rosenburg SA, eds. Cancer: principles and practice of oncology, 4th ed. Philadelphia: JB Lippincott, 1993:1264-332.
2. McPherson K, Steel CM, Dixon JM. Breast cancer - epidemiology, risk factors, and genetics. Br Med J 1994;309:1003-6.
3. Harris JR, Lippman ME, Veronesi U, et al. Breast cancer (third of three parts). N Engl J Med 1992;327:473-80.
4. Henderson IC. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, et al., eds. Breast diseases, 2nd ed. Philadelphia: JB Lippincott, 1991:604-65.
5. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semi-synthetic analog of Taxol. J Natl Cancer Inst 1991;83: 288-91.
6. Hanauske AR, Degen D, Hilsenbeck SG, et al. Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs 1992;3:121-4.
7. Aapro MS, Pujade-Lauraine E, Lhomme C, et al. EORTC Clinical Screening Group: phase II study of Taxotere in ovarian cancer. Ann Oncol 1994(suppl 5);5:202.
8. Trudeau M. Taxotere in breast cancer management. Cancer Invest 1993(suppl 1);12:35-6.
9. Kris MG. Docetaxel (Taxotere): a hemisynthetic taxoid active in lung cancer. Lung Cancer 1994(suppl 2);2:78-9.
10. Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5: 533-7.
11. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53:1037-42.
12. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11:950-8.
13. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993;53:523-7.
14. Pazdur R, Newman RA, Newman BM, et al. Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst 1992;84:1781-8.
15. Tomiak E, Piccart MJ, Kerger J, et al. A phase I study of Taxotere (RP 56976, NSC 628503) administered as a one hour intravenous (IV) infusion on a weekly basis. Eur J Cancer 1991(suppl 2);27:S194.
16. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995;13:314-22.
17. 2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 1996;74:650-6.
18. Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996;7:165-71.
19. Hudis CA, Seidman AD, Crown JPA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:58-65.
20. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996;14:422-8.
21. Taguchi T, Adachi I, Sasaki Y, et al. Docetaxel in advanced and recurrent breast cancer early and late phase II clinical trial in Japan. 19th Meeting of the European Society of Medical Oncology (ESMO). Lisbon, November 18-22, 1994.
22. Mouridsen HT: Systemic therapy of advanced breast cancer. Drugs 1992(suppl 4);44:17-28.
23. Ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994;5:527-32.
24. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-94.
25. Ravdin PM, Burris III HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-85.
26. Guastalla JP, Bonneterre J, Fumoleau P, et al. A phase II trial of docetaxel in patients (pts) with anthracycline resistant (AR) metastatic breast cancer (MBC). 8th ECCO, Paris, 29 Oct-2 Nov 1995 [abstract].
27. Taxotere, docetaxel. International Product Monograph 2nd ed. Rhône-Poulenc Rorer, 1996. ISBN 1 898970 26 2.
28. Klaassen U, Diergarten K, Dittrich CH, et al. Randomized trial of two doses of taxol in metastatic breast cancer: an interim analysis. Onkologie 1994;17:86-90.
29. Vermorken JB, ten Bokkel Huinink WW, Mandjes IAM, et al. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. Semin Oncol 1995;22:16-22.
30. Verweij J: Docetaxel (Taxotere): a natural breakthrough in the treatment of cancer. Eur J Cancer (in press).
31. Lemenager M, Genouville C, Bessa EH, et al. Docetaxel-induced alopecia can be prevented [Letter]. Lancet 1995;346: 371-2.
32. Eisenhauer EA, Lu F, Muldal A, et al. Predictors and treatment of docetaxel toxic effects. Ann Oncol 1994(suppl 5);5:202.
33. Galindo E, Kavanagh J, Fossella F, et al. Docetaxel (Taxotere) toxicities: analysis of a single institution experience of 168 patients (623 courses). Proc Am Soc Clin Oncol 1994;13:164.
34. Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol 1993;4:610-1.
35. Verweij J, Planting AST, Van der Burg MEL, et al. A phase I study of docetaxel (Taxotere) and cisplatin in patients with solid tumors. 19th Meeting of the European Society of Medical Oncology (ESMO), Lisbon, November 18-22, 1994.
36. Zalcberg J, Bishop JF, Webster LK, et al. A phase I trial of the combination Taxotere (docetaxel) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC). 19th Meeting of the European Society of Medical Oncology (ESMO), Lisbon, November 18-22, 1994.
37. Dieras V, Gruia G, Pouillart P, et al. A phase I study of the combination of docetaxel (D) and doxorubicin (DX) in 1st line CT treatment of metastatic breast cancer (MBC): preliminary results. [Abstract]. Breast Cancer Res Treat 1996(suppl);37:91.
38. Fumoleau P, Delecroix V, Perrocheau G, et al. Docetaxel (D) in combination with vinorelbine (V) as 1st line CT in pts with MBC: preliminary results on 22 entered patients [Abstract]. Breast Cancer Res Treat 1996(suppl);37:91.